Lexaria Featured on NetworkNewsWire Nicotine Delivery Methods Article

Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) was featured in a NetworkNewsWire article regarding alternatives to smoking cigarettes as a nicotine delivery method. The article presented Lexaria as a “company with proprietary technology capable of changing the way active pharmaceutical ingredients (“APIs”) such as nicotine enter the body,” making it an appealing solution to those wanting to phase out smoking from their lives.
Looking to change the way nicotine is consumed, Lexaria “is accelerating its research focus on nicotine following its patent grant and is preparing formulations of edible forms of nicotine using the DehydraTECH™ technology. These formulations are currently completing quality control testing prior to in vivo absorption and tolerability testing.”
To read the full article, click here.
Click here to connect with Lexaria Bioscience (CSE:LXX,OTCQB:LXRP) for an Investor Presentation